Ligand Pharmaceuticals to Host Annual Investor Day

• Ligand Pharmaceuticals will host its annual Investor Day on December 8, 2026, at the Harvard Club of New York City.
• Presentations will cover strategy, royalty investments and the long-term financial outlook.
• Palvella Therapeutics CEO Wes Kaupinen will discuss progress on QTORIN rapamycin, a treatment in development for rare diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ligand Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610221601PRIMZONEFULLFEED9851390) on October 22, 2026, and is solely responsible for the information contained therein.